Vasodilator therapy for acute heart failure: haemodynamic comparison of hydralazine/isosorbide, alpha-adrenoceptor blockade, and angiotensin-converting enzyme inhibition
- PMID: 1381019
Vasodilator therapy for acute heart failure: haemodynamic comparison of hydralazine/isosorbide, alpha-adrenoceptor blockade, and angiotensin-converting enzyme inhibition
Abstract
Haemodynamic comparison of three vasodilation regimens [intravenous (i.v.) hydralazine and isosorbide dinitrate (ISDN) combined, i.v. doxazosin, and i.v. enalaprilat] was undertaken in 36 patients with acute left ventricular (LV) failure due to recent myocardial infarction. Each regimen achieved similar reductions in pulmonary artery occluded pressure (PAOP, preload) and systemic arterial pressures (afterload), with increased cardiac and stroke volume (SV) indexes (p less than 0.01). Only the hydralazine and isosorbide combination induced resting tachycardia. Balanced vasodilatation after selective alpha-adrenoceptor blockade (doxazosin) and angiotensin-converting enzyme (ACE) inhibition (enalaprilat) without increase in heart rate (HR) suggests that these therapies may have definite haemodynamic advantages over the hydralazine/ISDN combination.
Similar articles
-
Current indications for vasodilator therapy for left ventricular failure.Compr Ther. 1985 Mar;11(3):39-46. Compr Ther. 1985. PMID: 2983926 No abstract available.
-
Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.N Engl J Med. 1986 Jun 12;314(24):1547-52. doi: 10.1056/NEJM198606123142404. N Engl J Med. 1986. PMID: 3520315 Clinical Trial.
-
Hemodynamic comparison of primary venous or arteriolar dilatation and the subsequent effect of furosemide in left ventricular failure after acute myocardial infarction.Am J Cardiol. 1983 Nov 1;52(8):1036-40. doi: 10.1016/0002-9149(83)90527-1. Am J Cardiol. 1983. PMID: 6637819 Clinical Trial.
-
Assessing the treatment of congestive heart failure: diuretics, vasodilators, and angiotensin-converting enzyme inhibitors.Pharmacotherapy. 1993 Sep-Oct;13(5 Pt 2):82S-87S. Pharmacotherapy. 1993. PMID: 8233997 Review.
-
[Cardiac failure and nitrates].Ann Cardiol Angeiol (Paris). 1997 Jul-Sep;46(7):415-9. Ann Cardiol Angeiol (Paris). 1997. PMID: 9452775 Review. French.
Cited by
-
Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.Cochrane Database Syst Rev. 2018 Jan 29;1(1):CD009669. doi: 10.1002/14651858.CD009669.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2020 Nov 5;11:CD009669. doi: 10.1002/14651858.CD009669.pub4. PMID: 29376560 Free PMC article. Updated.
-
Clinical pharmacokinetics of vasodilators. Part I.Clin Pharmacokinet. 1998 Jun;34(6):457-82. doi: 10.2165/00003088-199834060-00003. Clin Pharmacokinet. 1998. PMID: 9646008 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous